<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04365075</url>
  </required_header>
  <id_info>
    <org_study_id>XuanwuH202001</org_study_id>
    <nct_id>NCT04365075</nct_id>
  </id_info>
  <brief_title>Excimer Laser Combined With DCB Compared With Angioplasty Alone in the Treatment of Infrapopliteal Lesions.</brief_title>
  <official_title>Excimer Laser Combined With DCB Compared With Angioplasty Alone in the Treatment of Infrapopliteal Lesions in Patients With Critical Limb Ischemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xuanwu Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xuanwu Hospital, Beijing</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to compare excimer laser combined with drug-coated baloons with&#xD;
      angioplasty alone in the treatment of infrapopliteal lesions in patients with critical limb&#xD;
      ischemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized study comparing excimer laser combined with drug-coated baloons with&#xD;
      angioplasty alone in the treatment of infrapopliteal lesions in patients with critical limb&#xD;
      ischemia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target lesion revascularization rate</measure>
    <time_frame>6-months</time_frame>
    <description>Free target vascular occlusion and clinically driven target lesion revascularization rate confirmed by ultrasound examination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of major adverse events</measure>
    <time_frame>6-months</time_frame>
    <description>Incidence of major adverse events (including operative-related arterial dissection, perforation, rupture, embolization, acute thrombosis, pseudoaneurysm, and hematoma formation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major amputation rate</measure>
    <time_frame>6-months</time_frame>
    <description>The rate of major amputation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>6-months</time_frame>
    <description>The ratio of deaths</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankle Brachial Index</measure>
    <time_frame>6-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transcutaneous oxygen pressure</measure>
    <time_frame>6-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound healing wagner score (for patients with Rutherford classification 5)</measure>
    <time_frame>6-months</time_frame>
    <description>Wound healing wagner score (for patients with Rutherford classification 5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>6-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospitalization costs</measure>
    <time_frame>6-months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">184</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <condition>Infrapopliteal Lesions</condition>
  <arm_group>
    <arm_group_label>Excimer Laser Combined with DCB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Using excimer laser combined with drug-coated baloons to treat infrapopliteal lesions in patients with critical limb ischemia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Angioplasty Alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Using angioplasty alone to treat infrapopliteal lesions in patients with critical limb ischemia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Excimer Laser Combined with DCB</intervention_name>
    <description>Using excimer laser combined with drug-coated baloons to treat infrapopliteal lesions in patients with critical limb ischemia.</description>
    <arm_group_label>Excimer Laser Combined with DCB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Angioplasty Alone</intervention_name>
    <description>Using angioplasty alone to treat infrapopliteal lesions in patients with critical limb ischemia.</description>
    <arm_group_label>Angioplasty Alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The treatment vessel is DeNovo&#xD;
&#xD;
          -  Stenotic (&gt;50%) or occlusive atherosclerotic disease of infrapopliteal artery(s)&#xD;
&#xD;
          -  Reference target vessel diameter between 2-4.0 mm by visual assessment&#xD;
&#xD;
          -  Documented Rutherford Class 4 or 5 symptomatic critical limb ischemia&#xD;
&#xD;
          -  The patient must be &gt;18 years of age&#xD;
&#xD;
          -  Life-expectancy of more than 12 months&#xD;
&#xD;
          -  The patient has no child bearing potential or negative serum pregnancy test&#xD;
&#xD;
          -  within 7 days of the index procedure&#xD;
&#xD;
          -  The patient must be willing and able to return to the appropriate follow-up times for&#xD;
             the duration of the study&#xD;
&#xD;
          -  The patient must provide written patient informed consent that is approved by the&#xD;
             ethics committee&#xD;
&#xD;
        Anatomic Inclusion Criteria:&#xD;
&#xD;
          -  All inflow lesions successfully (&lt;30 residual stenosis) treated prior to target lesion&#xD;
             treatment during same procedure or according standard of care without unresolved&#xD;
             complications&#xD;
&#xD;
          -  At least one angiographically visible target at the ankle for establishment of&#xD;
             straight line flow.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient refusing treatment&#xD;
&#xD;
          -  The target vessel segment diameter is not suitable for available catheter design.&#xD;
&#xD;
          -  Unsuccessfully treated endovascular or bypass( &gt;30% residual stenosis) proximal (&#xD;
             iliac, superficial femoral, popliteal) inflow limiting arterial/graft stenosis&#xD;
&#xD;
          -  Lesion lies within or adjacent to an aneurysm&#xD;
&#xD;
          -  The patient has a known allergy to heparin, Aspirin or other antiaggregant therapies&#xD;
             or a bleeding diatheses or is unable, or unwilling, to tolerate such therapies.&#xD;
&#xD;
          -  The patient has a history of prior life-threatening contrast media reaction.&#xD;
&#xD;
          -  The patient is currently enrolled in another investigational device or drug trial.&#xD;
&#xD;
          -  The patient is currently breast-feeding, pregnant or intends to become pregnant.&#xD;
&#xD;
          -  The patient is unable to provide informed consent&#xD;
&#xD;
          -  The patient has end stage renal disease (currently on any form of dialysis)&#xD;
&#xD;
          -  Known Left Ventricular Ejection Fraction &lt; 35%&#xD;
&#xD;
          -  The patient has had a myocardial ischemia within 30 days prior to enrollment&#xD;
&#xD;
          -  The patient has had a cardiovascular accident within 90 days prior to enrollment&#xD;
&#xD;
          -  Serum Creatinine &gt; 150 Âµmol&#xD;
&#xD;
          -  The patient has a previous bypass in the target limb&#xD;
&#xD;
          -  The patient has a current systemic infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>jianming guo, M.D.</last_name>
    <phone>13146369562</phone>
    <email>guojianming@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>yongquan gu, M.D.</last_name>
    <phone>15901598209</phone>
    <email>gu15901598209@aliyun.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yongquan Gu</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jianming guo, M.D.</last_name>
      <phone>13146369562</phone>
      <email>guojianming@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 24, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Excimer Laser</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>drug-coated baloons</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

